A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Xu JZ, Conrey A, Frey I, Gwaabe E, et al. Blood 2022;140:2053-2062.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu JZ, Conrey A, Frey I, Gwaabe E, et al. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood 2022;140:2053-2062.
PMID: 35576529